Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Slow Start, St. Jude Says Portico TAVI Is Primed To Gain Traction

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical’s Portico transcatheter aortic valve is poised to become more competitive in Europe in 2014 as more sizes become available, executives told investors during the firm’s Feb. 7 annual investor conference. And the firm is talking to FDA about alternative pivotal trial designs.

You may also be interested in...

St. Jude Halts Portico TAVR Implants Based On IDE Study Imaging Data

The firm says it is temporarily halting implants of its transcatheter aortic health valve replacement worldwide while it reviews CT data showing reduced valve leaflet mobility in some patients treated as part of St. Jude’s U.S. pivotal trial.

New Product Briefs: St. Jude TAVR Update; ADHD, GI Tests Launch

St. Jude expects to receive a CE mark for a transfemoral 25 millimeter version of its Portico transcatheter aortic valve replacement system during the fourth quarter. NEBA Health launches ADHD test. Exalenz BioScience launches test for H. pylori stomach bacteria.

Transcatheter Valves At The Tipping Point

Although Edwards is the pioneer and market leader in TAVR, there is no shortage of competitors – in both the aortic and mitral valve segments – developing next-generation devices who would be happy with a fraction of this potential multibillion-dollar opportunity.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts